This isn’t just another drug trial. It’s about changing how doctors diagnose prostate cancer before jumping to biopsy. Right now, 3 million prostate biopsies happen globally each year; and up to 75% find nothing. That’s a lot of pain, stress, and cost for patients who didn’t need it. Telix’s imaging agents, Illuccix® and Gozellix®, combine with MRI to spot real cancer earlier; and more accurately. Early trials already cut unnecessary biopsies by nearly half. If BiPASS works, it could shift the standard across the U.S. and beyond. No more guessing games. No more waiting. Just smarter, faster, safer diagnosis. What’s even more interesting? Telix has already lined up with the FDA on how to get this approved; and reimbursed. That means, if successful, it won’t just be a breakthrough in medicine; it’ll actually reach patients. And that’s what matters most.